Literature DB >> 25813395

Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis.

M Vivas1, E Force2, F Tubau3, C El Haj2, J Ariza2, C Cabellos2.   

Abstract

This study aimed to determine the effect of dexamethasone in combination with low-dose or high-dose daptomycin for the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis. Efficacy (ΔCFU/mL) and cerebrospinal fluid (CSF) levels of daptomycin at 15mg/kg and 25mg/kg were studied in a rabbit model of pneumococcal meningitis, comparing them with the same doses in combination with dexamethasone at 0.125mg/kg every 12h over a 26-h period against two different Streptococcus pneumoniae strains, HUB 2349 and ATCC 51916 with daptomycin minimum inhibitory concentrations (MICs) of 0.09mg/L and 0.19mg/L, respectively. Daptomycin levels in CSF were lower when dexamethasone was given concurrently. Against strain HUB 2349, therapeutic failure occurred with daptomycin 15mg/kg+dexamethasone; daptomycin 25mg/kg+dexamethasone was better at reducing bacterial counts than the lower dose throughout treatment. Against the highly cephalosporin-resistant ATCC 51916 strain, daptomycin 15mg/kg+dexamethasone achieved a lower bacterial decrease than daptomycin 15mg/kg alone, and therapeutic failure at 24h occurred in the daptomycin 15mg/kg+dexamethasone group. Addition of dexamethasone to a 25mg/kg daptomycin dose did not affect the efficacy of daptomycin: it remained bactericidal throughout treatment. In conclusion, against the studied strains, low-dose (15mg/kg/day) daptomycin is affected by concomitant use of dexamethasone: CSF levels are reduced and its bacterial efficacy is affected. At a higher daptomycin dose (25mg/kg/day), however, the use of dexamethasone does not alter efficacy; the combination appears to be a good choice for the treatment of pneumococcal meningitis.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  CNS infection; Lipopeptide; Steroids; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2015        PMID: 25813395     DOI: 10.1016/j.ijantimicag.2015.01.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Characteristic Comparison of Meningitis and Non-meningitis of Streptococcus suis in an Experimentally Infected Porcine Model.

Authors:  Yingying Sun; Hongtao Liu; Rui Du; Shuguang Li; Guanggang Qu; Rining Zhu; Shuang Zhao; Jingmin Gu; Changjiang Sun; Xin Feng; Wenyu Han; Liancheng Lei
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 2.  Next generation protein based Streptococcus pneumoniae vaccines.

Authors:  Michael E Pichichero; M Nadeem Khan; Qingfu Xu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  The role of adjunctive dexamethasone in the treatment of bacterial meningitis: an updated systematic meta-analysis.

Authors:  Mei Shao; Peng Xu; Jun Liu; Wenyun Liu; Xiujie Wu
Journal:  Patient Prefer Adherence       Date:  2016-07-14       Impact factor: 2.711

4.  Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis.

Authors:  Ilias Masouris; Matthias Klein; Susanne Dyckhoff; Barbara Angele; H W Pfister; Uwe Koedel
Journal:  J Neuroinflammation       Date:  2017-11-02       Impact factor: 8.322

5.  Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis.

Authors:  S Piva; Antonello Di Paolo; Laura Galeotti; Francesco Ceccherini; Francesco Cordoni; Liana Signorini; Tommaso Togni; Amedeo De Nicolò; Frank A Rasulo; Nazzareno Fagoni; N Latronico; Antonio D'Avolio
Journal:  Neurocrit Care       Date:  2019-08       Impact factor: 3.210

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.